Clinical Trials in Netherlands — Country Dashboard | 2,588 EU Studies

Filter these 2,588 trials by condition, phase, sponsor and more.

Open in Search →

2,588 Registered trials

1,068 Recruiting

1,246 Completed trials

647 Sponsors active

360 Research sites

Phase III

Phase II

Phase III: 960 Phase II/III: 113 Phase II: 574 Phase I/II: 138 Phase III/IV: 55 Phase IV: 244 Phase I: 165 Phase I (Other): 215 Phase I (FiH): 110 Other: 13 Other: 1

Oversight events in trials active here:

116 serious breaches 513 temporary halts 35 urgent safety measures 70 unexpected events 90 corrective measures across 317 trials

View oversight register →

Top conditions

Non-small cell lung cancer 86 Non-small cell lung cancer metastatic 24 Amyotrophic lateral sclerosis 22 Crohn's disease 19 Prostate cancer metastatic 18 Colorectal cancer 17 Obesity 17 Colitis ulcerative 16 Diffuse large B-cell lymphoma 14 Systemic lupus erythematosus 13 Pulmonary arterial hypertension 13 Endometrial cancer 12

Top sponsors

Amsterdam UMC Stichting 103 Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) 94 Novartis Pharma AG 90 Merck Sharp & Dohme LLC 81 AstraZeneca AB 77 Universitair Medisch Centrum Groningen 70 F. Hoffmann-La Roche AG 64 Janssen - Cilag International 62 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 51 Radboud universitair medisch centrum Stichting 51 Boehringer Ingelheim International GmbH 50 Amsterdam UMC 47

Cities with most trials

All 123 cities →

All trials — page 42

2,588 total

Local Levobupivacaine for pain reflief after esophageal ESD Recruiting

2024-510912-66-00 Phase IV Visible esophageal lesions ((pre)cancerous) Sint Antonius Ziekenhuis Stichting
Remimazolam versus Midazolam for sedation during upper GI endoscopy: a randomized controlled trial Recruiting

2024-516432-94-00 Phase IV N/A Sint Antonius Ziekenhuis Stichting
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting

2023-509706-30-00 Phase III Heart failure (HF) Boehringer Ingelheim International GmbH
PERi-operative Selective Decontamination of the Digestive tract to prevent severe infectious complications after Esophagectomy: a Randomized… Recruiting

2023-504144-33-01 Phase III/IV esophageal cancer Stichting Radboud University Medical Center
Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects wi… Recruiting

2023-509334-19-00 Phase III gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) Rayzebio Inc.
Safety and efficacy of avalglucosidase alfa in patients with non-classic Pompe disease aged ≥ 5 years. Recruiting

2024-518215-18-00 Phase IV Glycogen storage disease type II or acid maltase deficiency,… Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
MCA-derived MSC therapy in renal transplant recipients Recruiting

2024-512553-25-00 Phase I (Other) Rejection transplanted kidney Leids Universitair Medisch Centrum (LUMC)
POPular GUILTY PILOT: Genotype-guided Clopidogrel monotherapy Recruiting

2024-518464-12-00 Phase IV Non-ST-segment Elevation Acute Coronary Syndrome Sint Antonius Ziekenhuis Stichting
DOSAgE study: A multicenter randomized phase III trial of DOSe-reduced Chemotherapy for Advanced Colorectal Cancer in Older patients Recruiting

2023-506115-17-00 Phase III Metastatic Colorectal Cancer Academisch Ziekenhuis Leiden
Can we Save the rectum by watchful waiting or transanal surgery following short- or long-course radioTherapy and Additional local oR systemi… Recruiting

2024-514620-17-00 Phase II Patients with early-stage rectal cancer (defined as early re… Radboud universitair medisch centrum Stichting
TAP-TAU Recruiting

2023-505430-10-00 Phase II/III Mild cognitive impairment and dementia Amsterdam UMC
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Recruiting

2023-508539-30-00 Phase II Refractory Focal Onset Epilepsy Biohaven Therapeutics Ltd.
IDE196 (Darovasertib) in Combination with Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Recruiting

2023-506686-66-01 Phase II/III HLA-A2 negative metastatic uveal melanoma Ideaya Biosciences Inc.
A Phase 2a, dose-finding, randomized, double-blinded, placebo-controlled study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safet… Recruiting

2023-509613-37-01 Phase I/II Alzheimer's Disease Amsterdam UMC
Uptake and biodistribution of 89Zirconium-labeled ipilimumab in ipilimumab treated patients with metastatic melanoma Recruiting

2024-516547-11-00 Phase II skincancer Stichting Amsterdam UMC
Rituximab-induced remission in CIDP (ReCIX study) Recruiting

2024-512506-25-00 Phase III Chronic inflammatory demyelinating polyneuropathy (CIDP) Amsterdam UMC Stichting
Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting

2023-508012-35-00 Phase III Newly diagnosed NSCLC with resectable clinical Stage II, III… Merck Sharp & Dohme LLC
A clinical imaging Study of the changes in [18F]F-AraG uptake following Radiotherapy in Non-small cell lung cancer. Recruiting

2024-517960-45-00 Phase I/II Melanoma Amsterdam UMC Stichting
Methylphenidate in KBG syndrome Recruiting

2023-506202-40-01 Phase IV KBG syndrome Stichting Radboud University Medical Center
An extension study for patients previously enrolled in studies with pelabresib Recruiting

2023-508950-24-00 Phase III Myelofibrosis Novartis Pharma AG
(NFPET) 89Zr-Bevacizumab PET/CT imaging in NF2 patients Recruiting

2024-512860-75-00 Phase II NF2-related schwannomatosis Leids Universitair Medisch Centrum (LUMC)
Tranexamic acid to prevent OpeRation in Chronic subdural Hematoma (TORCH) Recruiting

2024-514927-40-02 Phase III/IV Chronic Subdural Hematoma Stichting Amsterdam UMC
A study in people with obesity to test the effects of different doses of BI 456906 compared with semaglutide on glucagon receptor activity i… Recruiting

2024-515417-17-00 Phase I (Other) No targeted indication. Male and female subjects with obesit… Boehringer Ingelheim International GmbH
A lower dose olaparib, combined with a drug which inhibits olaparib degradation, to increase tolerability and decrease the price of the trea… Recruiting

2024-516414-38-00 Phase III/IV Cancer Stichting Radboud universitair medisch centrum

Showing 985–1,008 of 2,588 trials

← All countries